What the literature actually used.

Concentrations, not recommendations

GHK-Cu is not FDA-approved as a drug for any therapeutic indication, so there are no labeled human dose ranges. What this page records are the concentrations and routes used in published research — fibroblast collagen studies run at picomolar to nanomolar concentrations, rodent systemic studies at microgram-per-gram body weight, topical cosmetic formulations at roughly 0.05 to 3 percent by weight. Those numbers belong to specific studies and specific questions, not to a human dosing protocol. The skin-penetration literature notes that the free peptide is highly hydrophilic (clogP around minus two), and topical delivery strategies — liposomes, palmitoylated derivatives, microneedling — are an active area of formulation research precisely because the molecule does not cross intact skin easily without assistance.

Framing this section

This page summarizes the concentrations, routes, and durations used in published GHK-Cu research. It does not recommend a dose. GHK-Cu is recognized as a cosmetic ingredient (INCI: Copper Tripeptide-1) and is widely used in topical skincare; it is not FDA-approved as a drug for any therapeutic indication, and injectable GHK-Cu was placed on the FDA 503A interim Category 2 compounding list and removed without progression to Category 1.

Research-context numbers are best read as study attributes, not as protocols. 'Picomolar in fibroblast culture' describes the dose Maquart used to observe a doubling of collagen synthesis ^[1]. 'Microgram per gram intraperitoneal' describes the dose Zhang used to observe attenuation of cigarette-smoke-induced emphysema in mice ^[11]. Neither sentence is a recommendation.

A second framing note. The GHK-Cu literature does not converge on a single 'effective concentration' the way an FDA-approved drug label might. The dose-response window in vitro spans six orders of magnitude across published papers — picomolar for fibroblast collagen synthesis, micromolar for Connectivity Map gene-expression screens — and the topical and systemic literatures live on their own scales entirely. Reading the numbers below in that context is the point: each one belongs to a specific model and a specific question.

In vitro concentrations

Fibroblast and dermal-papilla cell work has converged on a narrow window. Maquart 1988 reported collagen-synthesis stimulation beginning at 10^-12 M and saturating around 10^-9 M ^[1] — that is, picomolar to low-nanomolar concentrations. Pyo 2007 used nanomolar tripeptide-copper in cultured human follicular dermal papilla cells and observed increased proliferation and longer in vitro hair shafts ^[7]. The Connectivity Map gene-expression work used 1 microM as the standardized screening concentration ^{[8][9][10][14]} — roughly three orders of magnitude above the collagen-stimulation threshold and chosen for signal strength in the screen rather than for biological realism.

Topical cosmetic formulations

Cosmetic-grade topical formulations of GHK-Cu typically run from 0.05% to 3% w/w in serum, cream, or eye-area products. The 2024 multicenter cosmetic study after fractional laser resurfacing used 0.05% GHK-Cu gel and reported approximately 25% faster epithelial recovery and roughly 30% lower IL-1beta and TNF-alpha in the GHK-Cu arm during the first 72 hours post-procedure [recent studies summary]. The 2002 Leyden 12-week facial cream study did not standardize concentration in the abstract but reported improvements in laxity, clarity, fine lines, density, and thickness in 71 women using twice-daily application ^[15]. The 2024 lipid-nano-carrier serum trial used twice-daily application for eight weeks in 40 women aged 40 to 65 and reported a 55.8% reduction in wrinkle volume and a 32.8% reduction in wrinkle depth by profilometry ^[17].

Formulation pH matters more than concentration alone. The copper(II) chelation is stable in a roughly neutral-to-slightly-acidic window; strongly acidic vehicles (low-pH vitamin C serums, certain exfoliating acids) can perturb the chelation and free the copper, which is one reason cosmetic protocols frequently separate GHK-Cu application from L-ascorbic acid application in time of day. The 2025 liposomal-delivery review highlights this and several adjacent measurement issues — standardized permeation-quantification methods are still lacking, and product-to-product comparison is therefore harder than the percentage on the label suggests ^[19].

Wound-bed and rodent systemic dosing

Rodent wound and systemic studies cover a wider dose range. The Maquart 1993 rat wound-chamber paper used nanomolar GHK-Cu infused locally and reached 396% of control collagen content at day 18 and 538% at day 22 ^[3]. The Canapp 2003 rat ischemic open-wound study used a topical gel and reported a 64.5% area reduction at day 13 versus 28.2% in controls ^[4]. The Wang 2017 mouse scald-wound study used topical liposomal GHK-Cu and observed faster closure, increased CD31+ vasculature, and increased proliferation markers ^[20].

The Zhang 2022 emphysema study used intraperitoneal GHK-Cu in C57BL/6J mice at 0.2, 2, or 20 microg/g body weight per day, dosed on alternate days for twelve weeks ^[11]. The dose range was chosen to bracket the threshold at which Nrf2 / Keap1 antioxidant induction became measurable; all three doses reduced emphysematous morphology and lowered IL-1beta and TNF-alpha in bronchoalveolar lavage.

Plasma half-life and route considerations

Free GHK-Cu has a short plasma half-life. Reported values range from minutes — consistent with rapid aminopeptidase cleavage of the N-terminal glycine — up to roughly 30 to 60 minutes after subcutaneous administration in animal models. Detectable serum levels typically fall below threshold within six to eight hours. Reconstituted aqueous GHK-Cu is reported stable about 28 days refrigerated and light-protected.

The combination of short half-life and hydrophilic chemistry constrains formulation. The dominant delivery strategies in the current research literature are liposomal and lipid-nano-carrier encapsulation ^[17][19][20], palmitoylated derivatives (Pal-GHK), and microneedle or iontophoresis pretreatment of skin ^[18]. Routes that have been studied at least in research models include topical (the cosmetic primary route), topical to wound bed, subcutaneous (research animals), intraperitoneal (rodent systemic models), intranasal (early Alzheimer's-model exploratory work), and transdermal via microneedle or iontophoresis.

Common cosmetic co-formulation context

The cosmetic literature frequently pairs GHK-Cu with other actives. Hyaluronic acid is a common co-formulation for hydration and extracellular-matrix support, with no known pharmacological interaction. Matrixyl 3000 (palmitoyl tripeptide-1 / palmitoyl tripeptide-7) appears alongside GHK-Cu in many anti-aging products, with the rationale being complementary collagen-signaling pathways. AHK-Cu (alanyl-histidyl-lysine copper), the sister copper tripeptide, sometimes appears in scalp serums where the hair-follicle stimulation evidence base is the draw. Retinoids and GHK-Cu are typically applied at different times of day in cosmetic protocols — the underlying mechanisms are complementary (retinoic acid pathway versus GHK gene-expression pathway) but the vehicle chemistries do not always co-exist comfortably.

These are observations about how formulators combine ingredients, not research-tested stack recommendations. The independent-active studies — Maquart's fibroblast work, the Mulder ulcer trial, the Leyden facial cream study, the Badenhorst lipid nano-carrier serum — were single-active or single-formulation, and the cleanest mechanistic evidence sits at the single-active end of that range.

Regulatory and translation context

Two regulatory notes that condition any dose conversation. First, GHK-Cu is not FDA-approved as a drug for any therapeutic indication; cosmetic use of Copper Tripeptide-1 is well established, but therapeutic use remains investigational. Second, injectable / systemic GHK-Cu was placed on the FDA 503A interim Category 2 compounding list and was removed without progression to Category 1, which means it is not currently eligible for 503A pharmacy compounding. Athletes should note that, while GHK-Cu is not currently listed by name on the WADA Prohibited List, listings change and current WADA documentation should be consulted before use.

A translation note. The systemic dose ranges that show up in rodent papers (the Zhang 0.2 to 20 microg/g intraperitoneal protocol, for example) do not have a corresponding labeled human equivalent, because no labeled human use of injectable GHK-Cu exists. Cross-species dose extrapolation is not a substitute for clinical-trial data, and the absence of large randomized human therapeutic trials is the single most consequential gap in the GHK-Cu file.